Lv21
174 积分 2025-02-27 加入
In vivo CAR-T therapy: The shift from ex vivo culturing to direct in situ immune reprogramming
10天前
已完结
Cascading attrition of in vivo CAR-T therapy: From systemic delivery failure to functional collapse
10天前
已完结
AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy
10天前
已完结
Cytokine co-presentation on targeted lipid nanoparticles enhances in vivo T cell engineering
11天前
已完结
Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor
13天前
已完结
The Pharmacology of CAR T Cell Therapy for Autoimmune Disease
13天前
已完结
The landscape of genetic medicines for in vivo T cell reprogramming
13天前
已完结
Resistance to CAR-based cell therapy: Mechanisms and overcoming strategies
28天前
已完结
Ultralow-Dose Interleukin 10–Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
28天前
已完结
Anti-CD19 CAR T-cell therapy as salvage treatment for refractory cutaneous polyarteritis nodosa
1个月前
已完结
皖公网安备34019202002308
